English
Email Chinese
2092018

I-Mab Wins Frost& Sullivan “2018 Best R&D Innovator Award (Biopharma Category)”

I-Mab Biopharma ("I-Mab") announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as the biggest growth consulting company in China, with...

1082018

I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 To Treat Type 2 Diabetes

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103)...

882018

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segm...

182018

I-Mab Biopharma Announces New CFO

I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focusing on innovative biologics in oncology and autoimmune disease, today announced the appointment of Jielun Zhu as Chief Financial Office...

2672018

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab Biopharma (“I-Mab”), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, and ABL Bio Corporation (“ABL Bio”), a South Korean biotechnology company...

2962018

I-Mab Successfully Raised US$220 Million in Series C Funding

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for $220 million USD...

762018

I-Mab Biopharma Opens US Office in Rockville, Maryland

Rockville MD—JUN 2018 — I-Mab Biopharma, announced the opening of its US office in Rockville, Maryland. The grand opening ceremony was honored by the presence of representatives from biotech and pharm...

25122017

I-Mab Biopharma signs licensing agreement for HyLeukin with Genexine

Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab Biopharma (I-Mab)....

1122017

I-Mab Biopharma and MorphoSys Partnership on Cancer Investigational Medicine

I-Mab and MorphoSys AG announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao....

2242017

天境生物与药明生物达成战略合作

上海,2017年4月10日——中国生物药领先企业天境生物与药明康德关联公司药明生物签署战略合作协议。根据该协议,药明生物将为天境生物提供包括肿瘤免疫疗法及治疗自身免疫系统疾病的多个抗体类药物的临床前药学研究...

Home Previous Next End 1/2page  13 10/page To:

Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com